PSA reduction, velocity during chemo predict survival
New Orleans--The amount and velocity of change in PSA during the first few months of chemotherapy can independently predict patients who will survive, according to data from the Southwest Oncology Group (SWOG) and Cancer and Leukemia Group B. The results are among many recent findings begging FDA consideration in the debate about how PSA measurements can be used to more quickly approve prostate cancer drugs.
Jessica Feehan, NP-C, discusses the expanding role of APPs in urology, from clinical leadership and procedures to care coordination and treatment initiation.
Sam S. Chang, MD, MBA, discusses treatment selection after BCG failure, including bladder-sparing options, cystectomy considerations, and the need for sequencing data.
Justin B. Ziemba, MD, discusses clinical factors that help identify patients at increased risk for kidney stone recurrence and guide metabolic evaluation.
Adam Sharp, PhD, BM, MRCP, BSc, discusses preliminary safety and efficacy findings from a phase 1/2 study of gedatolisib plus darolutamide in patients with mCRPC.